Guillain-Barre Syndrome Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Guillain-Barre Syndrome Market Analysis
The Guillain-Barre Syndrome Market studied is anticipated to grow at a CAGR of 5.2% during the forecast period, 2022-2027.
The Guillain-Barre syndrome (GBS) market was significantly impacted by COVID-19. Patients with Guillain-Barre syndrome were advised to take extra precautions to minimize the risk of getting COVID-19. Moreover, Guillain-Barre syndrome patients may not show typical symptoms such as a high temperature, and they may also experience a higher-than-normal pain threshold, which may delay the diagnosis of COVID-19. Furthermore, the article titled "Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study" published in Oxford Academic in September 2021, suggested that a COVID-19 infection may cause Guillain-Barré syndrome. The article further detailed that from January 30 to May 30, 2020, researchers analyzed individuals as part of the International GBS Outcome Study (or IGOS), a global cohort of individuals with Guillain-Barré syndrome. During this time, the study included an additional 49 Guillain-Barré syndrome patients from China, Denmark, France, Greece, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. In this cohort analysis, 22% of the Guillain-Barré syndrome patients had a preceding COVID-19 infection in the first 4 months of the pandemic. Such studies greatly highlighted the need for diagnosis and treatment of GBS, thereby boosting the market's growth over the pandemic phase.
Furthermore, the major factors contributing to the growth of the studied market are the increasing geriatric population, the growing prevalence of GBS, and product approval due to accelerated drug developments.
The rise in the geriatric population propels market growth over the forecast period. For instance, according to the World Health Organization's 2021 updates, by 2030, 1 out of every 6 people across the globe will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get doubled to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Furthermore, according to the study titled "Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019" published in the Journal of Neuroinflammation in November 2021, with growing age, the age-standardized burden of GBS increased and was higher in males across all age categories. The article provided first in-depth investigation of the prevalence and disability burden of Guillain-Barré syndrome (GBS) from 1990 to 2019 by cause, age, sex, and socio-demographic index (SDI) in 204 countries and territories. Thus, such instances are likely to propel the market's growth over the coming years.
In addition, the rise in new product approvals due to the accelerated drug approval initiative by the United States Food and Drug Administration is also boosting the market growth. For instance, in September 2019, Annexon Biosciences revealed that the United States Food and Drug Administration had granted fast-track designation to ANX005, a novel treatment for Guillain-Barré syndrome.
Thus, the aforesaid factors are likely to boost the growth of the market over the forecast period. However, higher challenges in the development stage, expensive patented products, and lack of awareness of the disease and effective treatment in the developing economies are the major restraining factors for the market studied.
Guillain-Barre Syndrome Market Trends
This section covers the major market trends shaping the Guillain Barre Syndrome Market according to our research experts:
Intravenous Immunoglobulin Segment is Expected to Hold the Large Market Share Over the Forecast Period
Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS, measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into the muscle, a vein, or under the skin.
Intravenous immunoglobulins are expected to account for a large share of the market, which can be attributed to the availability of a wide range of IVIG products such as Gamunex, Gammagard, and Privigen in the market and increased adoption of treatment by off-label use of intravenous immunoglobulins due to the rising prevalence of multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis. Furthermore, according to the Centers for Disease Control and Prevention, June 2022 update, GBS affects about 3,000-6,000 people each year in the United States. Such a burden of disease is fueling the demand for effective treatment, which is expected to drive the growth of the market segment over the forecast period.
In addition, increasing research studies for intravenous immunoglobulin (IVIG) are also expected to boost the growth of the market segment. For instance, in November 2021, the study titled "Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome" an interventional clinical trial by Assiut University is expected to be completed by December 2022. Such clinical studies may lead to the development of a newer products in the future and thus are expected to drive the growth of the market segment.
Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
North America Dominates the Market and Expected to do Same Over the Forecast Period.
North America is expected to dominate the overall GBS market throughout the forecast period. The dominance is due to several factors, such as the increasing geriatric population with higher chances of acquiring GBS, the presence of major market players, and growing awareness regarding GBS within the population.
According to the Centers for Disease Control and Prevention (CDC) article updated in June 2022, infection with Campylobacter jejuni, which causes diarrhea, is one of the most common causes of GBS. It also reported that people of any age group can develop GBS, but the risk of GBS increases in people aged over 50 years. Additionally, as per the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above, out of which 3,224,680 were males and 3,796,750 were females. Such an increase in the geriatric population coupled with the high risk of acquiring GBS is expected to boost the market's growth in the near future.
Moreover, the funding from public organizations for the different projects related to the GBS is expected to boost the growth of the market in North America. For instance, in October 2021, the National Institute of Neurological Disorders and Stroke (NINDS) approved USD 427,625 funding for co-investigators Brad Wright, Ph.D., Rebecca Traub, MD, and Chip Howard, MD for the project dealing with the understanding of Guillain-Barre syndrome using medicare claims and is expected to be completed by February 2023.
Thus, owing to the abovementioned factors, the studied market in the North American region is expected to boost the growth of the market.
Guillain-Barre Syndrome Industry Overview
The Guillain-Barre Syndrome market is moderately competitive and consists of several major players. Various strategies, such as the acquisition of the products by other companies, consolidate the market positions across the globe. Some of the companies currently dominating the market are Grifols S.A., CSL Limited, Octapharma AG, Kedrion Biopharma Inc., and Takeda Pharmaceutical Company Limited, among others.
Guillain-Barre Syndrome Market Leaders
-
CSL Behring LLC
-
Takeda Pharmaceutical Company Limited
-
Grifols SA
-
Kedrion Biopharma Inc.
-
Octapharma AG
*Disclaimer: Major Players sorted in no particular order
Guillain-Barre Syndrome Market News
- In March 2022, Annexon Biosciences presented preclinical data supporting complement inhibitor programs for the treatment of Guillain-Barré syndrome and Huntington's disease at the American Academy of Neurology (AAN) 2022.
- In December 2020, Annexon, Inc. reported that patient dosing has started in a Phase 2/3 clinical study of a full-length monoclonal antibody, ANX005, to treat Guillain-Barré Syndrome (GBS).
Guillain-Barre Syndrome Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Global Prevalence of GBS and Geriatric Population
- 4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA
-
4.3 Market Restraints
- 4.3.1 Higher Challenges in Development Stage and Expensive Patented Products
- 4.3.2 Lack of Awareness of Disease and Effective Treatment in the Developing Economies
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Therapeutics
- 5.1.1 Intravenous Immunoglobulin
- 5.1.2 Plasma Exchange
- 5.1.3 Others
-
5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Parenteral
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 CSL Limited
- 6.1.2 Takeda Pharmaceutical Company Limited
- 6.1.3 Grifols S A
- 6.1.4 Octapharma AG
- 6.1.5 Bayer AG
- 6.1.6 Kedrion Biopharma Inc
- 6.1.7 China Biologic Products Holdings Inc
- 6.1.8 Biotest AG
- 6.1.9 Annexon Inc.
- 6.1.10 Cellenkos inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGuillain-Barre Syndrome Industry Segmentation
As per the scope of the report, Guillain-Barre syndrome (GBS), also known as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), is an acute disorder characterized by paralyzed limbs, difficulty in breathing and facial movements, and inflammatory symptoms throughout the body due to an immune system attack on the peripheral nervous system. In this medical condition, the transmission of signals from nerves to the brain is prevented due to the formation of a covering over the myelin sheath, and the exact cause of GBS is not yet known. The Guillain Barre syndrome market is segmented by Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), Route of Administration (Oral, Parenteral) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Therapeutics | Intravenous Immunoglobulin | |
| Plasma Exchange | ||
| Others | ||
| By Route of Administration | Oral | |
| Parenteral | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Guillain-Barre Syndrome Market Research FAQs
What is the current Global Guillain-Barre Syndrome Market size?
The Global Guillain-Barre Syndrome Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Global Guillain-Barre Syndrome Market?
CSL Behring LLC, Takeda Pharmaceutical Company Limited, Grifols SA, Kedrion Biopharma Inc. and Octapharma AG are the major companies operating in the Global Guillain-Barre Syndrome Market.
Which is the fastest growing region in Global Guillain-Barre Syndrome Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Guillain-Barre Syndrome Market?
In 2024, the North America accounts for the largest market share in Global Guillain-Barre Syndrome Market.
What years does this Global Guillain-Barre Syndrome Market cover?
The report covers the Global Guillain-Barre Syndrome Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Guillain-Barre Syndrome Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Guillain-Barre Syndrome Industry Report
Statistics for the 2023 Guillain-Barre Syndrome market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Guillain-Barre Syndrome analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
